Roth Capital analyst Jotin Marango maintained a Hold rating on Flex Pharma (NASDAQ: FLKS) on June 29. The company’s shares closed on Friday at $0.94, close to its 52-week low of $0.92.
According to TipRanks.com, Marango is a 4-star analyst with an average return of 24.5% and a 50.0% success rate. Marango covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Aptevo Therapeutics Inc, and Aptose Biosciences.
Currently, the analyst consensus on Flex Pharma is a Moderate Buy with an average price target of $40.
See today’s analyst top recommended stocks >>
Based on Flex Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $8.22 million. In comparison, last year the company had a GAAP net loss of $8.8 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Flex Pharma, Inc. operates as a biotechnology company. It engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions. The company operates through the following business segments: Consumer Operations and Drug Development.
Read More on FLKS:
